SkinHealth Systems Gains FDA Clearance for Microneedling Device

Whitney Cypes, the company’s Chief Innovation Officer, noted that the regulatory approval bolsters their competitive standing in a rapidly expanding aesthetic market. Recent industry data shows consumer spending on microneedling procedures across U.S. practices climbed 33% in 2025.

The SkinStylus device is cleared to treat periorbital wrinkles, facial acne scars, and hypertrophic scarring resulting from surgery or trauma on the abdomen. By securing this clearance, SkinHealth Systems aims to capture a larger share of the clinical aesthetics sector as demand for non-invasive skin treatments continues to grow.